Clinical Trials Logo
  1. Home
  2. Congenital Myasthenic Syndrome
  3. NCT06078553

A Natural History Study in Participants With DOK7 Congenital Myasthenic Syndromes (CMS)

Congenital Myasthenic Syndrome Clinical Trial

Official title:
Multicenter, Multinational, Natural History Study in Participants With DOK7 Congenital Myasthenic Syndromes

Clinical Trial Summary

Participants will attend up to 3 study visits to collect clinical assessments. The assessments will evaluate participants' symptoms and quality of life to understand disease activity in patients with DOK7-CMS better and may inform future study design.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT06078553
Study type Observational
Source argenx
Contact Sabine Coppieters, MD
Phone 857-350-4834
Email clinicaltrials@argenx.com
Status Recruiting
Phase
Start date February 13, 2024
Completion date July 2025
View Details
See also
  Status Clinical Trial Phase
Completed NCT01203592 - Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes Phase 1
Recruiting NCT01403402 - Congenital Muscle Disease Study of Patient and Family Reported Medical Information
Recruiting NCT05687474 - Baby Detect : Genomic Newborn Screening
Completed NCT05408702 - Exercise in Autoimmune Myasthenia Gravis and Myasthenic Syndromes
Not yet recruiting NCT06436742 - A Phase 1b Study to Investigate Safety and Tolerability of ARGX-119 in Adult Participants With DOK7-Congenital Myasthenic Syndromes (CMS) Phase 1
Completed NCT01474980 - Pregnancy Outcomes in Congenital Myasthenie Syndrome N/A
No longer available NCT02189720 - Expanded Access Study Amifampridine Phosphate in Lambert-Eaton Myasthenic Syndrome (LEMS),Congenital Myasthenic Syndrome
No longer available NCT03062631 - Treatment Use of 3,4 Diaminopyridine in Congenital Myasthenia
Approved for marketing NCT00872950 - 3,4-Diaminopyridine Use in Lambert-Eaton Myasthenic Syndrome(LEMS) and Congenital Myasthenic Syndromes (CMS)